0FP4 Stock Overview
Pierrel S.p.A. engages in the development, production, registration, and licensing of synthetic drugs and medical devices for the oral health sector worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Pierrel S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.58 |
| 52 Week High | €2.80 |
| 52 Week Low | €1.58 |
| Beta | 0.47 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -92.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0FP4 | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0% | 5.0% | 1.7% |
| 1Y | n/a | 2.2% | 8.3% |
Return vs Industry: Insufficient data to determine how 0FP4 performed against the UK Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 0FP4 performed against the UK Market.
Price Volatility
| 0FP4 volatility | |
|---|---|
| 0FP4 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0FP4 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0FP4's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1948 | 105 | Fulvio Citaredo | www.pierrelgroup.com |
Pierrel S.p.A. engages in the development, production, registration, and licensing of synthetic drugs and medical devices for the oral health sector worldwide. It develops and markets dental anesthesia drugs under the Orabloc brand. The company also offers Goccles, a device for screening of the oral cavity.
Pierrel S.p.A. Fundamentals Summary
| 0FP4 fundamental statistics | |
|---|---|
| Market cap | €95.58m |
| Earnings (TTM) | €3.11m |
| Revenue (TTM) | €26.96m |
30.8x
P/E Ratio3.5x
P/S RatioIs 0FP4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0FP4 income statement (TTM) | |
|---|---|
| Revenue | €26.96m |
| Cost of Revenue | €13.35m |
| Gross Profit | €13.61m |
| Other Expenses | €10.50m |
| Earnings | €3.11m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.057 |
| Gross Margin | 50.48% |
| Net Profit Margin | 11.53% |
| Debt/Equity Ratio | 109.7% |
How did 0FP4 perform over the long term?
See historical performance and comparison